%0 Journal Article %1 Jahns1999 %A Jahns, R. %A Boivin, V. %A Siegmund, C. %A Boege, F. %A Lohse, M. J. %A Inselmann, G. %D 1999 %J J Am Coll Cardiol %K *Autoantibodies Aged Autoimmunity Cardiomyopathies/*immunology Chronic Disease Diseases/*complications Female Heart Humans Hypertension/*complications Male Middle Valve beta/*immunology Receptor Adrenergic %N 5 %P 1545-51 %T Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease %U http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10551705 %V 34 %X OBJECTIVES: We investigated whether autoantibodies against the human beta-adrenergic receptor (beta-AR) might be involved in cardiomyopathies secondary to valvular heart disease (VHD) or hypertensive heart disease (HHD). BACKGROUND: Autoimmunity to beta-AR has been proposed as a pathogenic principle in human cardiomyopathy. Recently, by the use of intact recombinant human beta-AR, we were able to confirm the existence of functionally active anti-beta-1-AR autoantibodies in patients with dilated cardiomyopathy (26% prevalence) or ischemic cardiomyopathy (10% prevalence); however, their prevalence in other (secondary) cardiomyopathies remained to be determined. METHODS: Immunoglobulin G (IgG) was prepared from the sera of 28 VHD and 19 HHD patients and first screened by a peptide-based enzyme-linked immunosorbent assay (antigens: aminoterminus, second extracellular loop ECII and carboxyterminus of human beta-1- and beta-2-AR). IgG from 108 gender- and age-matched healthy subjects served to define the threshold for positive immunoreactions. Positive sera were further screened for their ability to recognize and activate native human beta-AR situated in a cell membrane. RESULTS: Twenty-five percent (VHD) or 11% (HHD) of the patients and 4% of the healthy controls had IgG antibodies randomly directed against all the three domains tested and both beta-AR subtypes. Only one patient with aortic valve and concomitant coronary heart disease and one healthy subject had functionally active anti-b1-AR (targeting beta-1-ECII). Moreover, one HHD patient with concomitant collagenosis had IgG that was cross-reacting with recombinant beta-AR in immunological assays but was unable to affect receptor function. CONCLUSIONS: Autoimmune reactions against the human beta-AR do not appear to be associated with cardiomyopathies secondary to VHD or HHD.

@article{Jahns1999, abstract = {OBJECTIVES: We investigated whether autoantibodies against the human beta-adrenergic receptor (beta-AR) might be involved in cardiomyopathies secondary to valvular heart disease (VHD) or hypertensive heart disease (HHD). BACKGROUND: Autoimmunity to beta-AR has been proposed as a pathogenic principle in human cardiomyopathy. Recently, by the use of intact recombinant human beta-AR, we were able to confirm the existence of functionally active anti-beta-1-AR autoantibodies in patients with dilated cardiomyopathy (26% prevalence) or ischemic cardiomyopathy (10% prevalence); however, their prevalence in other (secondary) cardiomyopathies remained to be determined. METHODS: Immunoglobulin G (IgG) was prepared from the sera of 28 VHD and 19 HHD patients and first screened by a peptide-based enzyme-linked immunosorbent assay (antigens: aminoterminus, second extracellular loop [ECII] and carboxyterminus of human beta-1- and beta-2-AR). IgG from 108 gender- and age-matched healthy subjects served to define the threshold for positive immunoreactions. Positive sera were further screened for their ability to recognize and activate native human beta-AR situated in a cell membrane. RESULTS: Twenty-five percent (VHD) or 11% (HHD) of the patients and 4% of the healthy controls had IgG antibodies randomly directed against all the three domains tested and both beta-AR subtypes. Only one patient with aortic valve and concomitant coronary heart disease and one healthy subject had functionally active anti-b1-AR (targeting beta-1-ECII). Moreover, one HHD patient with concomitant collagenosis had IgG that was cross-reacting with recombinant beta-AR in immunological assays but was unable to affect receptor function. CONCLUSIONS: Autoimmune reactions against the human beta-AR do not appear to be associated with cardiomyopathies secondary to VHD or HHD.}, added-at = {2010-12-14T18:12:02.000+0100}, author = {Jahns, R. and Boivin, V. and Siegmund, C. and Boege, F. and Lohse, M. J. and Inselmann, G.}, biburl = {https://www.bibsonomy.org/bibtex/21ec378a4ae2e43a1dd26e1624ad8a143/pharmawuerz}, endnotereftype = {Journal Article}, interhash = {0a1b78be24d79767581bbb416225eec4}, intrahash = {1ec378a4ae2e43a1dd26e1624ad8a143}, issn = {0735-1097 (Print) 0735-1097 (Linking)}, journal = {J Am Coll Cardiol}, keywords = {*Autoantibodies Aged Autoimmunity Cardiomyopathies/*immunology Chronic Disease Diseases/*complications Female Heart Humans Hypertension/*complications Male Middle Valve beta/*immunology Receptor Adrenergic}, month = {Nov 1}, note = {Jahns, R Boivin, V Siegmund, C Boege, F Lohse, M J Inselmann, G Research Support, Non-U.S. Gov't United states Journal of the American College of Cardiology J Am Coll Cardiol. 1999 Nov 1;34(5):1545-51.}, number = 5, pages = {1545-51}, shorttitle = {Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease}, timestamp = {2010-12-14T18:22:40.000+0100}, title = {Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease}, url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10551705}, volume = 34, year = 1999 }